Cracking MYC addiction: Synthetic-lethal vulnerabilities for precision cancer therapy
Authors:
- Kaili DengKDKaili Deng
- Zhongyang HongZhongyang Hong
- Yuxin WangYWYuxin Wang
- Ye WuYWYe Wu
- Weidong ZhangWZWeidong Zhang
- Xin LuanXLXin Luan
- Zhe SunZSZhe Sun
Open Access
- 1 October 2026
- journal article
- Published by KEAI Publishing in Genes & Diseases
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China
This publication has 127 references indexed in Scilit:
- Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosisCancer Cell, 2025
- MLCK inhibition induces synthetic lethality in MYC-driven cancerCancer Letters, 2025
- Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabineJournal of Neuro-Oncology, 2020
- Direct Phosphorylation and Stabilization of MYC by Aurora B Kinase Promote T-cell LeukemogenesisCancer Cell, 2020
- Karyopherins in cancerCurrent Opinion in Cell Biology, 2018
- MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase InhibitionCancer Cell, 2017
- Deregulated Myc Requires MondoA/Mlx for Metabolic Reprogramming and TumorigenesisCancer Cell, 2015
- Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood NeuroblastomaCancer Cell, 2013
- Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53Cancer Cell, 2012
- MYC on the Path to CancerCell, 2012